Skip to content

A pilot investigation of a single session of stimulation of the left frontal brain area applying a technique that delivers localised magnetic waves through the skull (repetitive transcranial magnetic stimulation [rTMS]) in people with a bulimic eating disorder (e.g. bulimia nervosa and binge-eating disorder) who engage in binge-eating behaviour and its effect on craving, bingeing behaviour and mood and stress

A pilot investigation of the effects of repetitive transcranial magnetic stimulation (rTMS) in bulimic disorders: a two-armed double-blind randomised sham (placebo)-controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN95300084
Enrollment
40
Registered
2009-11-04
Start date
2008-06-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bulimic eating disorders Mental and Behavioural Disorders Eating disorders

Interventions

rTMS will be delivered with a Magstim Rapid device, with real and sham figure-eight coils (Magstim, Whitland, Wales, UK). Following mapping of the abductor pollicis brevis site in the left motor corte

Sponsors

King's College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Outpatients 2. Male and female 3. Aged 18 to 60 years 4. Body mass index (BMI) higher than 17.5 kg/m^2 5. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis of bulimia nervosa, binge eating disorder or eating disorder not otherwise specified (EDNOS) with a minimum of six binge episodes in the last 28 days (as assessed by the Eating Disorder Examination - Questionnaire [EDE-Q])

Exclusion criteria

Exclusion criteria: 1. Having a history of head or eye injury 2. Having a history of a neurological disease including previous seizures of any kind 3. Having metallic implants in the head 4. Being on a dose of any psychotropic medication that has not been stable for at least 14 days prior to participation in the study 5. Being pregnant 6. Smoking more than 10 cigarettes/day 7. Having any substance dependence 8. Participants who vomit on a regular basis (i.e. greater than 7 x a week), will be required to have a blood test to exclude those with electrolytes below the normal range 9. Participants will not have any other major psychiatric disorder needing treatment in its own right 10. Contraindications to rTMS as assessed with the Adult Safety Screen Questionnaire for rTMS 11. Being primarily left-handed

Design outcomes

Primary

MeasureTime frame
The food craving score scored as 'urge to eat' on a 10 cm visual analogue scale (VAS) once before and once after real or sham rTMS (0 = no urge to eat at all; 10 extremely strong urge to eat).

Secondary

MeasureTime frame
1. The score on a 10 cm 'tension' VAS (0 = extremely calm; 10 = extreme tense) once just before and once just after real or sham rTMS 2. The score on a 10 cm 'mood' (0 = extremely low mood; 10 = extreme high mood) VAS once before and once after real or sham rTMS 3. The score on a 10 cm 'hunger' (0 = not hungry at all; 10 = extreme hungry) VAS once before and once after real or sham rTMS 4. The score on a 10 cm 'urge to binge-eat' (0 = no urge to binge eat; 10 = extreme strong urge to binge eat) VAS once before and once after real or sham rTMS 5. The score on a 10 cm 'urge to purge' (0 = no urge to be sick or purge; 10 extremely strong urge to be sick or purge) VAS once before and once after real or sham rTMS 6. The score on the Food Craving Questionnaire - State once before and once after real or sham rTMS 7. The number or participants who have a binge in the 24 hours period after real or sham rTMS, measured 24 hours after the real or sham rTMS session 8. The 'interference' score on the Stroop Colour Word Task once before and once after real or sham rTMS (calculated as the difference between time to complete the 'colour word' card and time to complete the 'colour' card) 9. Salivary cortisol levels (Salivette®) at four time points, two before and two after real or sham rTMS 10. Percentage of drop-out in real and sham rTMS, measured at the end of the real or sham rTMS session 11. Percentage of people reporting adverse-events after real of sham rTMS immediately after the real or sham rTMS session and 24 hours after the real or sham rTMS session

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026